Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
A growing body of evidence indicates that antivascular endothelial growth factor (VEGF) therapy is effective in the treatment of retinopathy of prematurity (ROP). We conducted a comprehensive literature review on refractive outcomes of anti-VEGF treatments compared to laser treatment or a combination of laser therapy and anti-VEGF injections. Of the 9 studies analyzed, the final mean refractive error was myopic in 3 studies (37%) with IVB monotherapy, 7 studies (87.5%) with laser photocoagulation, and 1 study (50%) with combined therapy. In comparing IVB with laser monotherapy, 6 of 7 studies (86%) reported that final refractive error was significantly more myopic (>1 D) after laser treatment. No study was graded as high quality, and only a single article provided moderate quality of evidence.
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Kaveh
K
Abri Aghdam
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Joobin
J
Khadamy
Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran; Department of Ophthalmology, David Geffen School of Medicine, University of California-Los Angeles. Electronic address: drghasemi@yahoo.com.
Khalil Ghasemi
KG
Falavarjani
Department of Ophthalmology, David Geffen School of Medicine, University of California-Los Angeles.
Irena
I
Tsui
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation; D012178:Retinopathy of Prematurity / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab